TORONTO, ONTARIO / ACCESSWIRE / April 15, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that it is advancing on its sales and marketing mandate through the hiring of Mr. Derek Small as Director of Sales and Marketing.
Mr. Small has over 15 years of experience in the sale and marketing of medical devices in Canada and the US. Mr. Small's background includes growth from $0 to $20 million in annual revenue in 5 years, with increasing roles and responsibilities as a senior sales manager of an US based aesthetic laser company.
Under the leadership of Mr. Small, the vision of the Company for 2014 is to grow its Canadian and US sales and marketing through the hiring of a direct sales force comprised of: Territory Sales Managers, Inside Sales Representatives and marketing personnel. Canada will be subdivided into 3 main territories: Western Canada, Ontario and Eastern Canada, coinciding with the largest Canadian cities of Vancouver, Calgary, Toronto and Montreal, The US will be subdivided into 5 main territories: Northeast, Southeast, Midwest, South and Southwest, coinciding with the largest US cities of New York, Miami, Chicago, Dallas and Los Angeles.
The vision of the Company for 2015 is to grow its international revenue through selection and appointment of master distributors and country- specific distributors, who would retain exclusive distribution rights in a particular territory in exchange for meeting and surpassing minimum quarterly and annual revenue objectives.
Derek Small, Director of Sales and Marketing for Theralase Inc. stated that, "It is a pleasure to join the Theralase team and to execute on their vision. Their current therapeutic laser system, the TLC-1000, is a best-in-class technology that has helped millions of patients eliminate their pain throughout Canada. I look forward to growing the sales and marketing team of Theralase over 2014 and 2015 to achieve the Company's strategic quarterly and annual revenue objectives. The next generation therapeutic laser and anti-cancer technology that the Company is currently developing will be the catalyst that launches the Company's revenue into the stratosphere through this newly minted sales and marketing team. The opportunity at Theralase bears close relationship to one of my previous positions, where I dramatically increased the revenue of the organization through the hiring of top-notch sales and marketing talent and the launch of world-class technology. I am confident that I can repeat the same success with Theralase, as their technology is clearly state-of-the-art."
Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated that, "I am delighted that the Company has attracted the talents of an accomplished sales professional, with a strong history of success in significantly increasing medical device company sales from $0 to $20 million in sales in 5 years. Derek has been given the mandate from the Company to assemble a highly skilled team of Territory Sales Managers, Inside Sales Managers and marketing personnel in 2Q2014 and 3Q2014 to execute on the Company's vision of dramatically growing revenue in 2014 and 2015. I wish Derek success in his current mandate."
"Theralase is preparing to launch its next generation TLC-2000 biofeedback therapeutic laser technology in 4Q2014 that will revolutionize the therapeutic laser industry. This new, patented cold laser technology will provide patient specific treatments that adapt to a patient's physical characteristics delivering best-in-class performance in the elimination of pain, inflammation and acceleration of tissue healing. The medical community and patients who experience pain have been waiting for a technology of this efficacy and performance to enter the market. Derek will be in charge of launching this new technology in Canada and the US in 4Q2014, through his newly assembled sales and marketing team", Roger Dumoulin-White, President and CEO of Theralase went on to say.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint conditions. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
SOURCE: Theralase Technologies Inc.
Leave a comment...